For instance, one study based on 126 patients receiving CAR-T cell therapy (the target antigens of these cells included CD19, CD22, and BCMA) reported 33 (26%) cardiovascular (CV) events, with heart failure (HF), acute coronary syndrome (ACS), and arrhythmias being the top 3 CV events (22). This evidence concerns the gene CD19 and Arrhythmia.